(Q34189114)

31 July 2017

1 reference

title

Pharmacokinetic-pharmacodynamic modeling: why? (English)

1 reference

31 July 2017

1 reference

1 reference

Pérez-Urizar J

1

1 reference

31 July 2017

Granados-Soto V

series ordinal

2

1 reference

31 July 2017

Flores-Murrieta FJ

series ordinal

3

1 reference

31 July 2017

Castañeda-Hernández G

series ordinal

4

1 reference

31 July 2017

publication date

1 November 2000

1 reference

Archives of Medical Research

31 July 2017

published in

1 reference

31 July 2017

volume

31

1 reference

31 July 2017

issue

6

1 reference

31 July 2017

page(s)

539-545

1 reference

Pharmacokinetic-pharmacodynamic relationships in phase I/phase II of drug development

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Pharmacokinetic and pharmacodynamic data and models in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Role of pharmacokinetic-pharmacodynamic principles in rational and cost-effective drug development.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Physiologically based pharmacokinetic/pharmacodynamic modeling of chemical mixtures and possible applications in risk assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Physiological indirect effect modeling of the antilipolytic effects of adenosine A1-receptor agonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

First-time-in-human dose selection: allometric thoughts and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Mechanism-based pharmacodynamic modeling

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Predicting effective drug concentrations for individual patients. Determinants of pharmacodynamic variability

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Pharmacokinetic-pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Comparison of four basic models of indirect pharmacodynamic responses

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Physiologic indirect response models characterize diverse types of pharmacodynamic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Application of pharmacodynamic modeling for designing time-variant dosing regimens to overcome nitroglycerin tolerance in experimental heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Drug- or hormone-induced adaptation: model of adrenergic hypersensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Kinetics of drug action in disease states III: Effect of pregnancy on the relationship between phenytoin concentration and antiseizure activity in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Methodological issues in pharmacokinetic-pharmacodynamic modelling.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Efficacy measures: surrogates or clinical outcomes?

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Thiopental pharmacodynamics. II. Quantitation of clinical and electroencephalographic depth of anesthesia

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Prediction of therapeutic doses of beta-adrenergic receptor blocking agents based on quantitative structure-pharmacokinetic/pharmacodynamic relationship

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Pharmacokinetics and pharmacodynamics following intravenous doses of azimilide dihydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

A MOLECULAR BASIS FOR DRUG ACTION.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Characterization of the analgesic effect of paracetamol and caffeine combinations in the pain-induced functional impairment model in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Integrated pharmacokinetic-pharmacodynamic model for acetaminophen, ibuprofen, and placebo antipyresis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Influence of drug formulation on drug concentration-effect relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Simultaneous Modeling of Pharmacokinetics and Pharmacodynamics with a Nonparametric Pharmacodynamic Model

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Pharmacodynamic system analysis of the biophase level predictor and the transduction function.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

The use of the plasma concentration-effect relationship as a tool for the study of the mechanism of action of naloxone effects on mood and endocrine function.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Phamacokinetic-pharmacodynamic modelling of behavioural responses.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Pharmacodynamic modeling of nonsteroidal anti-inflammatory drugs: antipyretic effect of ibuprofen

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Pharmacokinetic-pharmacodynamic modeling of tolmetin antinociceptive effect in the rat using an indirect response model: a population approach

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Population pharmacokinetic modeling: the importance of informative graphics

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

Software for population pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900242-3

7 January 2021

10.1016/S0188-4409(00)00242-3

Identifiers

DOI

1 reference

31 July 2017

1 reference